February 4, 2023
Cosentyx demonstrated sustained efficacy and symptom improvement in HS patients.
Novartis presented the long-term data of SUNSHINE and SUNRISE trials, demonstrating the efficacy and symptom improvement in moderate-to-severe hidradenitis suppurativa patients.
Over 55% of patients achieved HS Clinical Response (HiSCR) at Week 52, and 60% were free of flares. Over 50% of patients had reduced pain, a burdensome symptom in HS patients.
No new safety signals were observed in the HS trials. Novartis announced that it submitted the data to Europe and United States regulatory agencies. Cosentyx, if approved, will be the first interleukin-17 inhibitor that would be approved for moderate-to-severe HS.